Higbee's Copyright Extortion Fizzles: A Web Host's Epic Smackdown
Demand letter lands. Panic sets in. But May First Movement Technology didn't fold. They shredded Higbee's shakedown with cold, hard law.
Everyone figured OpenAI's IPO was imminent. Instead, they're hoovering up $122 billion privately — with retail investors chipping in $3B — rewriting the script on AI's money game.
Demand letter lands. Panic sets in. But May First Movement Technology didn't fold. They shredded Higbee's shakedown with cold, hard law.
Picture AI models as unruly rockets blasting off without seatbelts. The EU AI Act's Chapter V slams on the brakes—with enforcement powers igniting in 2026.
Medicare's AI is playing doctor—and screwing patients. EFF just sued to expose the mess.
AI's rocketing past human experts — think OpenAI's o3 crushing benchmarks. Paris 2025 summit aims to slam the brakes with global action. Buckle up.
Cash-strapped founders: your next MSA could cost $500, delivered overnight. AI-native firms aren't tweaking old models—they're rebuilding law from silicon up.
Matt Pollins just unleashed a directory of AI-native law firms. Twenty-seven NewMods already — and counting. Big Law's wake-up call has arrived.
A California jury just slapped Meta with liability for its addictive features. But celebrating that ignores how appeals—and Section 230—will likely flip the script, protecting speech we all rely on.
The EU AI Act promised uniform innovation boosters. Reality? A patchwork of sandboxes, with Denmark already testing AI and laggards barely sketching plans.
Seventy-nine percent. That's how many Americans say Congress must hold feds accountable for ignoring privacy laws. CDT's new coalition push could finally force a reckoning.
Governments promised safety nets online. Instead, they're casting drag nets over activists. EFF's UN submission pulls no punches on the digital crackdown.
€15 million fines — or 3% of global revenue — loom for AI modifiers who misread the EU AI Act. Practitioners who've built on GPT warn: one tweak can flip you from user to regulated provider.
Stealth biotech firm R3 Bio didn't just fund monkey 'organ sacks'—its founder eyed brainless human clones as eternal spare parts. Ethics alarms blare as markets weigh the taboo.